Key Highlights
- Adagio Medical Holdings (NASDAQ:ADGM) fell 29.93% to about USD 0.0604 in trading on November 5, 2026, per published market data, a day after announcing a reverse split.
- The 1-for-30 reverse split takes effect November 6, 2026, after stockholder and board approval on October 23, 2026, and combines every 30 shares into one.
- A September 23, 2026 filing cut 25 of 43 full-time jobs, at an estimated cash cost of about USD 1.3 million, while the board explores strategic alternatives.
- Preliminary cash and marketable securities were about USD 7.7 million at June 30, 2026, against 13% senior secured convertible notes with a floating conversion price.
Reverse Split Lands After a Strategic Review
On November 4, 2026, Adagio Medical Holdings (NASDAQ:ADGM) announced an amendment implementing a 1-for-30 reverse stock split, approved by the board and stockholders on October 23, 2026. Every 30 outstanding common shares will be combined into one, fractional shares will be paid in cash, and options, restricted stock units and warrants will be adjusted proportionally. The split is effective November 6, 2026, and published coverage indicates split-adjusted trading on Nasdaq from November 9, 2026. In trading on November 5, 2026, the stock fell 29.93% to about USD 0.0604, with market Capitalization of roughly USD 1.66 million, per published market data. The move follows a September 23, 2026 decision to open a formal strategic review.
Cash, Notes and the Dilution Mechanism
A reverse split does not change what a company is worth. It cuts the share count and lifts the quoted price, usually to restore a minimum bid. The harder issue is financing. In a September 23, 2026 8-K, Adagio told holders of its 13% senior secured convertible notes that, through October 31, 2026, the conversion price would be the lower of the existing price or 85% of the lowest five-day volume-weighted average price. When a stock falls, that formula hands noteholders more shares per dollar converted, adding Supply and pressure. The same filing disclosed preliminary unaudited cash, equivalents and marketable securities of about USD 7.7 million at June 30, 2026, and a workforce cut of 25 of 43 employees.
Clinical Progress and Risks to Watch
The clinical story is intact on paper. A premarket approval application for the vCLAS cryoablation system went to the FDA on May 21, 2026, backed by FULCRUM-VT pivotal data from 209 patients across 20 centers, which showed 84% freedom from shock and 59% freedom from ventricular tachycardia recurrence. A next-generation system began its IDE study on September 16, 2026. Funding is the constraint. Third-quarter results are expected on November 11, 2026, per published coverage. At this size, a small number of trades can move the price, spreads can be wide, and quoted moves can reverse. Reverse-split names often drift after the adjustment, and nothing here implies the decline or any rebound will continue.
Where Things Stand
The 29.93% drop in Adagio Medical Holdings (NASDAQ:ADGM) reflects a financing squeeze rather than a clinical setback. The reverse split, a convertible note formula that reprices lower as the stock falls, thin cash and an open-ended strategic review give holders little visibility. The FDA review of vCLAS and the FULCRUM-VT dataset remain the core value. Watch the split-adjusted open, the November 11, 2026 results, noteholder conversions and any transaction announcement.






Please wait processing your request...